Charles N. York II - 15 Nov 2022 Form 4 Insider Report for Day One Biopharmaceuticals, Inc. (DAWN)

Role: COO, CFO and Secretary
Signature: /s/ Charles N. York II
Issuer symbol: DAWN
Transactions as of: 15 Nov 2022
Net transactions value: -$9,228
Form type: 4
Filing time: 17 Nov 2022, 16:49:00 UTC
Previous filing: 03 Nov 2022
Next filing: 22 Nov 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DAWN	Common Stock	Options Exercise		+1,375	+0.47%		295,776	15 Nov 2022	Direct	F1
transaction	DAWN	Common Stock	Sale	$9,228	-430	-0.14%	$21.46	296,497	16 Nov 2022	Direct	F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	DAWN	Restricted Stock Units	Options Exercise	$0	-1,375	-7.7%	$0.000000	16,500	15 Nov 2022	Common Stock	1,375		Direct	F1, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration.
F2	The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of RSUs.
F3	Includes 1,151 shares of Common Stock acquired under the Issuer's employee stock purchase plan on November 16, 2022.
F4	The RSUs will vest as to 1/12 of the total award in quarterly installments on February 15th, May 15th, August 15th, and November 15th, subject to the Reporting Person's continued service to the Issuer on each vesting date.